Article
Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
BMC cancer - 6 May 2020
Ejegod Ditte Møller, Lagheden Camilla, Bhatia Ramya, Pedersen Helle, Boada Elia Alcañiz, Sundström Karin, Cortés Javier, Josë F Xavier Bosch, Cuschieri Kate, Dillner Joakim, Bonde Jesper
Abstract excerpt
BACKGROUND: To ensure the highest quality of human papillomavirus (HPV) testing in primary cervical cancer screening, novel HPV assays must be evaluated in accordance with the international guidelines. Furthermore, HPV assay with genotyping capabilities are becoming increasingly important in triage of HPV positive women in primary HPV screening. Here we evaluate a full genotyping HPV assay intended for primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.